KB-1304

JNJ64407564-GPRC5D-hIgG1

33673

Home » Antibodies » JNJ64407564-GPRC5D-hIgG1

Background of JNJ64407564-GPRC5D-hIgG1

GPRC5D is a highly expressed target on multiple myeloma cells, while CD3 is the main component of the T cell receptor (TCR) and plays a critical role in activating T cells. By targeting both of these targets simultaneously, Talquetamab can activate T cells more effectively, attack multiple myeloma cells, and reduce side effects. Talquetamab (JNJ-63483043) is an innovative investigational drug that offers a new approach to the treatment of multiple myeloma. It is a ready-to-use, off-the-shelf immunotherapy that targets both GPRC5D and CD3 through bispecific antibody technology.

Specifications

Catalog Number	KB-1304
Antibody Name	JNJ64407564-GPRC5D-hIgG1
Isotype	Human IgG1,kappa
Target	GPRC5D
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA \| FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol 2015;12:42–54.
Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M, et al Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 2012;42:953–60.